As Mirati Therapeutics INC (MRTX) Stock Rose, Broadfin Capital LLC Lowered Its Holding

July 16, 2018 - By Carolyn Hewitt

Mirati Therapeutics, Inc. (NASDAQ:MRTX) LogoInvestors sentiment decreased to 1.76 in 2018 Q1. Its down 0.45, from 2.21 in 2017Q4. It fall, as 9 investors sold MRTX shares while 16 reduced holdings. 27 funds opened positions while 17 raised stakes. 19.53 million shares or 9.99% more from 17.76 million shares in 2017Q4 were reported. Venbio Select Advisor Ltd has invested 6.45% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Dimensional Fund Advsrs LP has invested 0% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Northern Corp reported 60,341 shares. Eam Invsts Ltd Company reported 61,030 shares. Element Management Limited Com holds 32,680 shares or 0.02% of its portfolio. Acadian Asset Mngmt Limited Liability Corp reported 0% stake. Bankshares Of America Corporation De owns 2,839 shares for 0% of their portfolio. Rock Springs Cap Mgmt Limited Partnership accumulated 0.25% or 189,000 shares. Susquehanna Grp Incorporated Llp reported 47,189 shares stake. Thompson Davis And Com has invested 0.1% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). State Street Corp owns 697,707 shares for 0% of their portfolio. Pennsylvania-based Federated Invsts Pa has invested 0% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Citadel Lc reported 49,176 shares or 0% of all its holdings. Raymond James Finance Advsrs holds 0% or 7,562 shares. Pnc Group reported 92 shares.

Since January 26, 2018, it had 2 insider purchases, and 6 sales for $18.20 million activity. $15.54M worth of Mirati Therapeutics, Inc. (NASDAQ:MRTX) shares were bought by venBio Select Advisor LLC. Christensen Jamie had sold 22,000 shares worth $726,040. $423,500 worth of Mirati Therapeutics, Inc. (NASDAQ:MRTX) shares were sold by Donadio Jamie A. BAUM CHARLES M had sold 51,810 shares worth $1.45M.

Kevin Kotler decreased its stake in Mirati Therapeutics Inc (MRTX) by 41.01% based on its latest 2018Q1 regulatory filing with the SEC. Broadfin Capital Llc sold 1.00M shares as the company’s stock rose 54.53% while stock markets declined. The hedge fund run by Kevin Kotler held 1.44 million shares of the health care company at the end of 2018Q1, valued at $44.33 million, down from 2.45M at the end of the previous reported quarter. Broadfin Capital Llc who had been investing in Mirati Therapeutics Inc for a number of months, seems to be less bullish one the $1.55B market cap company. The stock decreased 0.71% or $0.35 during the last trading session, reaching $48.9. About 175,821 shares traded. Mirati Therapeutics, Inc. (NASDAQ:MRTX) has risen 1243.94% since July 16, 2017 and is uptrending. It has outperformed by 1231.37% the S&P500.

Broadfin Capital Llc, which manages about $1.26 billion and $641.74 million US Long portfolio, upped its stake in Vericel Corp by 572,342 shares to 658,900 shares, valued at $6.56 million in 2018Q1, according to the filing. It also increased its holding in Zogenix Inc by 80,300 shares in the quarter, for a total of 537,380 shares, and has risen its stake in Horizon Pharma Plc (NASDAQ:HZNP).

Analysts await Mirati Therapeutics, Inc. (NASDAQ:MRTX) to report earnings on August, 2. They expect $-0.78 earnings per share, down 5.41 % or $0.04 from last year’s $-0.74 per share. After $-0.51 actual earnings per share reported by Mirati Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 52.94 % negative EPS growth.

More news for Mirati Therapeutics, Inc. (NASDAQ:MRTX) were recently published by: Streetinsider.com, which released: “Mirati Therapeutics (MRTX) PT Raised to $64 at Citi on Positive Interim Phase 2 Data for Sitra Plus Nivo; ‘IO Refractory …” on July 05, 2018. Benzinga.com‘s article titled: “Benzinga’s Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street” and published on June 21, 2018 is yet another important article.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Ratings Coverage

Among 4 analysts covering Mirati Therapeutics (NASDAQ:MRTX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Mirati Therapeutics had 4 analyst reports since March 5, 2018 according to SRatingsIntel. Citigroup maintained Mirati Therapeutics, Inc. (NASDAQ:MRTX) on Monday, March 5 with “Buy” rating. As per Wednesday, April 25, the company rating was maintained by H.C. Wainwright. The company was maintained on Thursday, March 8 by SunTrust.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.